Depression, major depression
Conditions
Interventions
After signing informed consent, participants will be invited to the neurofeedback laboratory of the school for Mental Health and Neuroscience (MheNS). This laboratory is a facility that meets the requ
.
At the start of each NF session, the baseline EEG is being measures without NF to assess baseline AA which serves as a starting point for feedback. Measuring baseline prior to each session is neces
Sponsors
Prof. Dr. F.P.M.L. Peeters
Afdeling Psychiatrie
Academisch Ziekenhuis Maastricht
Postbus 5800
6202 AZ Maastricht
Tel : 043-3874130
Fax : 043-3875444
E-mail: f.peeters@maastrichtuniversity.nl
Eligibility
Inclusion criteria
Inclusion criteria: In order to be eligible to participate in this study, a subject must meet all of the following criteria: • Primary axis-1 disorder of Major Depressive Disorder fulfilling DSM-IV criteria [14]. The diagnosis will be based on resuls from the Structured Interview for DSM-IV [15], that is an element of the diagnostic work-up at the RIAGG Maastricht. • Written informed consent.
Exclusion criteria
Exclusion criteria: A potential subject who meets any of the following criteria will be excluded from participation in this study: • History of brain trauma (commotio or constusio cerebri) or CVA. • Current use of antipsychotics, moodstabilizers or benzodiazepines. Current use of antidepressants is permitted if this medication is not changed within a period of 6 weeks prior to participation in the study. Additionally, no changes in antidepressant medication are allowed during active participation in the study. • Chronic depression (> two years duration). • Dysthymia as a primary axis-1 diagnosis • Bipolar disorder or schizophrenia as a primary axis-1 diagnosis • Severe suicidality (HDRS item # 3 with a score >2) or severe depression symptomatology (HDRS score > 25). • Pregnancy. • Age 65 years. • Daily alcoholintake of >7 units.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Depression severity as assessed with the Quick Inventory of Depressive Symptoms (QIDS-SR; [18], and the Hamilton Depression Rating Scale (HDRS; [19]. •The QIDS-SR is a 16-item self-rating scale to assess symptom severity of MDD and will be administered prior to each NF session (3 times a week). •The HDRS is a 17-item clinician-rated scale for estimating severity of depression during the past week. It will be administered once a week by a trained research assistant during the 6-week study period. | — |
Secondary
| Measure | Time frame |
|---|---|
| Remission from Depression Questionnaire (RDQ; [20] and change in AA between frontal cortical regions. • The RDQ is a 41-item self-rating scale that measures symptomatic and functional remission from depression. It will be administrated once a week during the 6-week study period. • AA in frontal regions (F3-F4) will be calculated as described in the intervention paragraph above. Other study parameters • Demographical data-sheet (date of birth, gender, educational level, marital status). • The State-Trait Anxiety Inventory (STAI). This instrument measures state and trait anxiety based on 40 items [21]. • General health before and after the treatment will be measured with the RAND-36. Based on 36 items, various dimensions of general health are being measured [22]. • After their last NF-session, participants will be asked to indicate whether, in their opinion, they have received active or sham-treatment. • Questionnaire “Classificatie van links- en rechtshandige proefpersonen” [23]. | — |
Contacts
Public ContactF.P.M.L. Peeters
Department of Psychiatry University Hospital Maastricht P.O. Box 5800
Outcome results
None listed